Starpharma (ASX:SPL) receives EU approval for anti-COVID nasal spray

Company News

by Michael Luu

Pharmaceutical developer Starpharma (ASX:SPL) has received EU approval for the company’s antiviral nasal spray Viraleze.

Studies have shown that the product is effective in combating respiratory viral diseases such as COVID-19. Experts believe the spray can hinder the spread of the coronavirus, when used in conjunction with vaccines and public health mechanisms. Starpharma expects to have enough supply for distribution into the European market from next month.

Shares in Starphama (ASX:SPL) are trading 5.45 per cent higher at $2.32

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.